These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30463041)

  • 1. Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions.
    Parry MG; Sujenthiran A; Cowling TE; Charman S; Nossiter J; Aggarwal A; Clarke NW; Payne H; van der Meulen J
    Cancer Epidemiol; 2019 Feb; 58():44-51. PubMed ID: 30463041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence.
    Westerberg M; Beckmann K; Gedeborg R; Irenaeus S; Holmberg L; Garmo H; Stattin P
    J Clin Epidemiol; 2023 Mar; 155():22-30. PubMed ID: 36538980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of using multiple imputation for "unknown" stage at diagnosis in population-based cancer registry data.
    Luo Q; Egger S; Yu XQ; Smith DP; O'Connell DL
    PLoS One; 2017; 12(6):e0180033. PubMed ID: 28654653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.
    Cook MB; Hurwitz LM; Geczik AM; Butler EN
    Eur Urol; 2021 Jan; 79(1):33-41. PubMed ID: 33092896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
    Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
    J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of various assumptions for the individual TNM components on the TNM stage using Nordic cancer registry data.
    Engholm G; Lundberg FE; Kønig SM; Ólafsdóttir E; Johannesen TB; Pettersson D; Mørch LS; Johansson ALV; Friis S
    Acta Oncol; 2023 Mar; 62(3):215-222. PubMed ID: 36961761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
    Stattin K; Sandin F; Bratt O; Lambe M
    J Urol; 2015 Dec; 194(6):1594-600. PubMed ID: 26192253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of cases with unknown stage prostate cancer in a population-based cancer registry.
    Luo Q; Yu XQ; Cooke-Yarborough C; Smith DP; O'Connell DL
    Cancer Epidemiol; 2013 Dec; 37(6):813-9. PubMed ID: 24103424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993-2014.
    Saito E; Hori M; Matsuda T; Yoneoka D; Ito Y; Katanoda K
    Cancer Epidemiol Biomarkers Prev; 2020 Jun; 29(6):1222-1228. PubMed ID: 32169995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collection of population-based cancer staging information in Western Australia--a feasibility study.
    Threlfall T; Wittorff J; Boutdara P; Heyworth J; Katris P; Sheiner H; Fritschi L
    Popul Health Metr; 2005 Aug; 3():9. PubMed ID: 16105180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imputation of missing values of tumour stage in population-based cancer registration.
    Eisemann N; Waldmann A; Katalinic A
    BMC Med Res Methodol; 2011 Sep; 11():129. PubMed ID: 21929796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England.
    Jack RH; Davies EA; Møller H
    BJU Int; 2010 May; 105(9):1226-30. PubMed ID: 19878505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    Di Girolamo C; Walters S; Benitez Majano S; Rachet B; Coleman MP; Njagi EN; Morris M
    BMC Cancer; 2018 May; 18(1):492. PubMed ID: 29716543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data.
    Parry MG; Cowling TE; Sujenthiran A; Nossiter J; Berry B; Cathcart P; Clarke NW; Payne H; Aggarwal A; van der Meulen J
    Cancer Epidemiol; 2019 Dec; 63():101628. PubMed ID: 31715436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Audit of prostate cancer: validity and feasibility of registry-based staging.
    Silcocks P; Needham P; Hemsley F
    Public Health; 1999 Jul; 113(4):157-60. PubMed ID: 10483075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple imputation to minimise bias from missing stage information in estimates of early cancer diagnosis in England: a population-based study.
    Muller P; Woods L
    Cancer Epidemiol; 2022 Aug; 79():102198. PubMed ID: 35724558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan.
    Masaoka H; Ito H; Yokomizo A; Eto M; Matsuo K
    Cancer Sci; 2017 Aug; 108(8):1673-1680. PubMed ID: 28594447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-related hospitalisations and 'unknown' stage prostate cancer: a population-based record linkage study.
    Luo Q; Yu XQ; Smith DP; Goldsbury DE; Cooke-Yarborough C; Patel MI; O'Connell DL
    BMJ Open; 2017 Jan; 7(1):e014259. PubMed ID: 28077413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.